These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 10418915)

  • 41. Investigation of cellular and humoral immune responses to whole cell and acellular pertussis vaccines.
    Canthaboo C; Williams L; Xing DK; Corbel MJ
    Vaccine; 2000 Nov; 19(6):637-43. PubMed ID: 11090715
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evolution of
    Bouchez V; Guillot S; Landier A; Armatys N; Matczak S; ; Toubiana J; Brisse S
    Euro Surveill; 2021 Sep; 26(37):. PubMed ID: 34533118
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic and antigenic analysis of Bordetella pertussis isolates recovered from clinical cases in Ontario, Canada, before and after the introduction of the acellular pertussis vaccine.
    Tsang RS; Sill ML; Martin IE; Jamieson F
    Can J Microbiol; 2005 Oct; 51(10):887-92. PubMed ID: 16333349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pertactin-negative Bordetella pertussis strains in Canada: characterization of a dozen isolates based on a survey of 224 samples collected in different parts of the country over the last 20 years.
    Tsang RS; Shuel M; Jamieson FB; Drews S; Hoang L; Horsman G; Lefebvre B; Desai S; St-Laurent M
    Int J Infect Dis; 2014 Nov; 28():65-9. PubMed ID: 25244999
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Manifestations and Molecular Characterization of Pertactin-Deficient and Pertactin-Producing Bordetella pertussis in Children, Philadelphia 2007-2014.
    Vodzak J; Queenan AM; Souder E; Evangelista AT; Long SS
    Clin Infect Dis; 2017 Jan; 64(1):60-66. PubMed ID: 27624959
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage.
    Martin SW; Pawloski L; Williams M; Weening K; DeBolt C; Qin X; Reynolds L; Kenyon C; Giambrone G; Kudish K; Miller L; Selvage D; Lee A; Skoff TH; Kamiya H; Cassiday PK; Tondella ML; Clark TA
    Clin Infect Dis; 2015 Jan; 60(2):223-7. PubMed ID: 25301209
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pertactin-Deficient Bordetella pertussis with Unusual Mechanism of Pertactin Disruption, Spain, 1986-2018.
    Mir-Cros A; Moreno-Mingorance A; Martín-Gómez MT; Abad R; Bloise I; Campins M; González-Praetorius A; Gutiérrez MN; Martín-González H; Muñoz-Almagro C; Orellana MÁ; de Pablos M; Roca-Grande J; Rodrigo C; Rodríguez ME; Uriona S; Vidal MJ; Pumarola T; Larrosa MN; González-López JJ
    Emerg Infect Dis; 2022 May; 28(5):967-976. PubMed ID: 35447067
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes.
    Gaillard ME; Bottero D; Errea A; Ormazábal M; Zurita ME; Moreno G; Rumbo M; Castuma C; Bartel E; Flores D; van der Ley P; van der Ark A; F Hozbor D
    Vaccine; 2014 Feb; 32(8):931-7. PubMed ID: 24397896
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
    Van der Wielen M; Van Damme P; Joossens E; François G; Meurice F; Ramalho A
    Vaccine; 2000 Apr; 18(20):2075-82. PubMed ID: 10715521
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cell-mediated immunity after pertussis vaccination and after natural infection.
    Zepp F; Knuf M; Habermehl P; Schmitt HJ; Meyer C; Clemens R; Slaoui M
    Dev Biol Stand; 1997; 89():307-14. PubMed ID: 9272364
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simple Algorithm for Identification of Bordetella pertussis Pertactin Gene Variants.
    Muyldermans G; Piérard D; Hoebrekx N; Advani R; Van Amersfoorth S; De Schutter I; Soetens O; Eeckhout L; Malfroot A; Lauwers S
    J Clin Microbiol; 2004 Apr; 42(4):1614-9. PubMed ID: 15071014
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Molecular genetic characteristics of the B. pertussis strains isolated in different periods of the pertussis epidemic process].
    Mazurova IK; Borisova OIu; Kombarova SIu; Zakharova NS; Aleshkin VA
    Mol Gen Mikrobiol Virusol; 2005; (4):21-5. PubMed ID: 16334221
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.
    Boros CA; Hanlon M; Gold MS; Roberton DM
    Vaccine; 2001 May; 19(25-26):3537-42. PubMed ID: 11348721
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Screening and Genomic Characterization of Filamentous Hemagglutinin-Deficient Bordetella pertussis.
    Weigand MR; Pawloski LC; Peng Y; Ju H; Burroughs M; Cassiday PK; Davis JK; DuVall M; Johnson T; Juieng P; Knipe K; Loparev VN; Mathis MH; Rowe LA; Sheth M; Williams MM; Tondella ML
    Infect Immun; 2018 Apr; 86(4):. PubMed ID: 29358336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012.
    Zeddeman A; van Gent M; Heuvelman CJ; van der Heide HG; Bart MJ; Advani A; Hallander HO; Wirsing von Konig CH; Riffelman M; Storsaeter J; Vestrheim DF; Dalby T; Krogfelt KA; Fry NK; Barkoff AM; Mertsola J; He Q; Mooi F
    Euro Surveill; 2014 Aug; 19(33):. PubMed ID: 25166348
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection.
    Denoël P; Poolman J; Carletti G; Veitch K
    Vaccine; 2002 Jun; 20(19-20):2551-5. PubMed ID: 12057612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins.
    Khelef N; Bachelet CM; Vargaftig BB; Guiso N
    Infect Immun; 1994 Jul; 62(7):2893-900. PubMed ID: 7999145
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bordetella pertussis population dynamics and phylogeny in Japan after adoption of acellular pertussis vaccines.
    Zomer A; Otsuka N; Hiramatsu Y; Kamachi K; Nishimura N; Ozaki T; Poolman J; Geurtsen J
    Microb Genom; 2018 May; 4(5):. PubMed ID: 29771235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.